US20100331355A1 - Substituted Quinolines for the Treatment of Cancer - Google Patents
Substituted Quinolines for the Treatment of Cancer Download PDFInfo
- Publication number
- US20100331355A1 US20100331355A1 US12/760,408 US76040810A US2010331355A1 US 20100331355 A1 US20100331355 A1 US 20100331355A1 US 76040810 A US76040810 A US 76040810A US 2010331355 A1 US2010331355 A1 US 2010331355A1
- Authority
- US
- United States
- Prior art keywords
- indolo
- quinoline
- radical
- carboxamide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C(BC)C2=C(C([4*])=Ccn2C)C([3*])=C1[2*].[1*]C1=C([4*])C2=C(C(BC)=Ccn2C)C([3*])=C1[2*] Chemical compound [1*]C1=C(BC)C2=C(C([4*])=Ccn2C)C([3*])=C1[2*].[1*]C1=C([4*])C2=C(C(BC)=Ccn2C)C([3*])=C1[2*] 0.000 description 29
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KURWKDDWCJELSV-UHFFFAOYSA-N CN1C2=CC=CC=C2C=C2N=C3C=CC=CC3=C21 Chemical compound CN1C2=CC=CC=C2C=C2N=C3C=CC=CC3=C21 KURWKDDWCJELSV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to new compounds which intercalate between DNA base pairs. Such compounds can be used for the treatment of cancer.
- Intercalators are a group of compounds that bind between the DNA base pairs. This intercalation can produce an interruption of transcription, replication and/or topoisomerase activity. It has been found that many compounds that bind to DNA by intercalation have antiproliferative properties and in vivo antitumour effects. Intercalators have been used as anticancer drugs. Cryptolepine is a naturally occurring alkaloid and it is used in traditional medicine against malaria. Its formula, shown below, is structurally close to some compounds of the present invention. Cryptolepine is able to bind CG-rich sequences of DNA containing non-alternating CC sites, and it has been reported as potential anticancer drug (cf. e.g. J. N.
- -G 1 is a radical selected from (IIa) y (IIb);
- R′ is an electron pair or a (C 1 -C 3 )-alkyl radical
- radicals (IIa) and (IIb) are respectively (IIa′) and (II′), and
- radicals (IIa) and (IIb) are respectively (IIa′′) and (IIb′′);
- —R 1 to —R 12 represent radicals, same or different, selected from the group consisting of H, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;
- —B— is a biradical selected from the group consisting of —CONH—
- (C 1 -C 4 )-alkylamino; —R′′ are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3; m is an integer from 1 to 3; u is an integer from 1 to 3, and —Z— is a biradical of a oligonucleotide phosphate between 4 and 23 bases in length, linked to the methylene group at the 5′ end or at the 3′ end;
- -L- is a single covalent bond or a covalent linking biradical selected from the following ones;
- R′′′ and —R′′′′ are radicals, same or different, selected from the group consisting of H and (C 1 -C 3 )-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and
- -G 2 is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine;
- compounds of formula (I) are those where (IIa) is the radical (IIa′).
- Preferred compounds are those of formula (I) where (IIa) is (IIa′) and —B— is
- —Z— is -TTCCGGAA- linked at 3′ end or at 5′ end, or -CTTCTTCTTCT- linked at 3′ end.
- -L- is a single covalent bond.
- -L- is a covalent linking biradical selected from the following ones.
- compounds of formula (I) are those where (IIa) is the following radical.
- Preferred compounds are those where (IIa) is (IIa′′) and —B— is —CONH— or
- the most preferred compounds of formula (I) are those of the following list, whose preparation is described in the accompanying examples for the first time: N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia); N,N′-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Ib);
- Another aspect of the present invention refers to the use of the compound of formula (I), defined above, for the preparation of a medicament for the treatment of cancer.
- a further aspect of the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of formula (I), defined above, together with suitable pharmaceuticalexcipients or carriers.
- the 11-aminocarboxylic radical selected from formula (IIa) or the 4-aminocarboxylic radical selected from formula (IIb) is coupled by benzotriazol-1-yloxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and diisopropylamine, followed by acidolysis.
- PyBOP benzotriazol-1-yloxytripyrrolidinophosphonium hexafluoro-phosphate
- Compounds of formula (I) may be converted into pharmaceutically acceptable acid addition salts, and salts may be converted into free compounds, by conventional methods.
- the acid addition salts may be prepared by contacting the free base with an appropriate amount of the desired acid in a conventional manner.
- Compounds of formula (I) are intercalators (i.e. compounds which intercalate between DNA base pairs) and, as illustrated by biological results in example 30 are active for cancer treatment.
- 9-acridinecarboxylic acid (0.036 g, 0.16 mmol) was dissolved in 3 ml of refluxing SOCl 2 . After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 4 ml of CH 2 Cl 2 . A solution of 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methyl-amino]propyl]-11-carboxamide (0.076 g, 0.19 mmol) and triethylamine (0.2 ml) in 4 ml of CH 2 Cl 2 was added at room temperature, and the reaction mixture was stirred for 14 hours.
- 1,8-naphthalic anhydride (0.18 g, 0.9 mmol) was added to a solution of [3-[(3-aminopropyl)methylamino]propyl]carbamic acid tert-butyl ester previously prepared (Spicer at el., Bioorg. Med. Chem. 2002, vol. 10, p. 19) (0.2 g, 0.8 mmol) in absolute ethanol (20 ml). The reaction mixture was heated at reflux overnight.
- 9-acridinecarboxylic acid (0.15 g, 0.67 mmol) was dissolved in 15 ml of refluxing SOCl 2 . After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 15 ml of CH 2 Cl 2 . A solution of 10H-indolo[3,2-b]quinoline-[2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]-11-carboxamide (0.4 g, 0.92 mmol) and triethylamine (1 ml) in 15 ml of CH 2 Cl 2 was added at room temperature. The reaction mixture was stirred for 14 hours.
- the 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid is known in the literature as part of extract plant Cryptolepis sanguinolenta (cf. Paulo et al., Planta Medica 2000, vol. 66, p. 30). It can also be prepared by the following process:
- the compound of the title was prepared by solid phase methods. After assembling the Boc-glicine-arginine sequence on a p-methylbenzhydrylamine resin, the N-terminal was deprotected and 10H-indolo[3,2-b]quinoline-11-carboxylic acid was coupled by means of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and diisopropylethylamine (5, 5 and 10 equivalents, respectively) in 1:1 DMSO-DMF for 1 h. Acidolysis with HF/anisole (9:1, 0° C., 1 h) provided the desired compound in highly homogeneous form (>98% by HPLC). MS(MALDI-TOF): EM(expected): 474.1; EM(found): 475.5 (M+H + ).
- 5′TTCCGGAA-NH 2 -3′ oligonucleotide sequence carrying an amino group at the 3′ end was prepared using 3-O-dimethoxytrityloxy-2-(N-9-fluorenphenylmethoxycarbonyl-4-aminobutyl)-1-propanyl ester succinamidyl-controlled pore glass (3′ amino C7 modifier CPG from Glen Research).
- the solid support obtained after the assembly of the sequence was treated with a 0.1 M solution of 1,8-diazabiciclo[5.4.0]undece-7-ene (DBU) in dry acetonitrile (2 min, room temperature). In this way, the Fmoc group that protects the amino group is removed selectively with a non-nucleophillic base.
- DBU 1,8-diazabiciclo[5.4.0]undece-7-ene
- 3′ oligonucleotide sequence carrying an amino group at the 3′ end was prepared using the 3′ amino C7 modifier CPG (Glen Research).
- the solid support obtained after the assembly of the sequence was treated with concentrated ammonia for 1 hr at 50° C.
- the mixture was filtered and the ammonia solution was concentrated to dryness.
- the residue was passed over a Dowex 50 ⁇ 4 (Na+ form) column to exchange ammonium ions for sodium ions.
- the resulting amino-oligonucleotide was dissolved in 0.1 ml of water, and mixed with 0.1 ml of 1M sodium carbonate aqueous buffer pH 8-9.
- HPLC solutions were as follows: Solvent A: 5% ACN in 100 mM triethylammonium acetate pH 6.5 and solvent B: 70% ACN in 100 mM triethylammonium acetate pH 6.5.
- the desired product was characterized by the UV-spectra. UVmax: 258, 348 and mass spectrometry (MALDI-TOF): found 2861 (M+H + ) expected 2862. Yield: 18%.
- the compound of the title was obtained in a similar way to example 16 but ammonia treatment was run for 2 hours at room temperature.
- the compound of the title eluted at 13.8 min. It was characterized by the UV-spectra. UVmax: 273, 349. Yield: 5%.
- the compound of the title was obtained in a similar way to example 17.
- the compound of the title eluted at 13.9 min. It was characterized by the UV-spectra. UVmax: 273, 349, and mass spectrometry (MALDI-TOF): found 3646 (M+H + ) expected 3647. Yield: 20%.
- 5′NH 2 -TTCCGGAA 3′ oligonucleotide sequence carrying an amino group at the 5′ end was prepared using the phosphoramidite of the N6-monomethoxytrityl (MMT) protected derivative of 6-aminohexanol (Glen Research).
- MMT N6-monomethoxytrityl
- the solid support obtained after the assembly of the sequence was treated with concentrated ammonia for 1 hr at 50° C.
- Reaction of the 5′ amino-oligonucleotide with 10H-indolo[3,2-b]quinoline-11-carboxylic acid was carried out as described in example 17.
- the desired product was characterized by the UV-spectra UVmax: 268, 349. Yield: 12%.
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.066 g, 0.25 mmol) was dissolved in 3 ml of refluxing SOCl 2 . After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH 2 Cl 2 . A solution of 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methyl-amino]propyl]-4-carboxamide (0.14 g, 0.36 mmol) and triethylamine (0.2 ml) in 2 ml of CH 2 Cl 2 was added at room temperature, and the reaction mixture was stirred for 14 hours.
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.009 g, 0.034 mmol) was dissolved in 2 ml of refluxing SOCl 2 . After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH 2 Cl 2 . A solution of 10H-indolo[3,2-b]quinoline-11-carboxylic acid(2-[3-(2-amino-ethylamino)-propylamino]-ethyl]-amide (0.02 g, 0.049 mmol) and triethylamine (0.2 ml) in 2 ml of CH 2 Cl 2 was added at room temperature.
- the in vitro cytotoxicity of the compounds of the present invention was evaluated by colorimetric assays with tetrazol salts (MTT) on Jurkat clon E6-1 and on GLC-4, human leukemia and carcinoma cell lines, respectively.
- This assay is based on the capacity of live cells to incorporate and reduce the MTT, with yellow colour in a red derivative. This reduction is done by the action of the mitochondrial enzyme succinate hydrogenase, only active in live cells. The intensity of observed colour is directly correlated with the quantity of live cells in the sample as it is described by Mosmann et al., J. Immunol. Methods 1983, vol. 65, p. 55. In all cases the concentrations used were up to 100 mikroM and times of incubation until 72 h. Table 1 shows the biological activity (IC 50 ) of some compounds of formula (I)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
- This invention relates to new compounds which intercalate between DNA base pairs. Such compounds can be used for the treatment of cancer.
- Intercalators are a group of compounds that bind between the DNA base pairs. This intercalation can produce an interruption of transcription, replication and/or topoisomerase activity. It has been found that many compounds that bind to DNA by intercalation have antiproliferative properties and in vivo antitumour effects. Intercalators have been used as anticancer drugs. Cryptolepine is a naturally occurring alkaloid and it is used in traditional medicine against malaria. Its formula, shown below, is structurally close to some compounds of the present invention. Cryptolepine is able to bind CG-rich sequences of DNA containing non-alternating CC sites, and it has been reported as potential anticancer drug (cf. e.g. J. N. Lisgarten et al., “The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites”, Nature Structural Biology 2002, vol. 9, pp. 57-60). Thus, the provision of new intercalators with anticancer activity is highly desirable.
- According to an aspect of the present invention, there is provided a compound of formula (I),
-
G1-L-G2 1. -
- (ii) (I)
- or a pharmaceutically acceptable salt thereof, wherein:
- -G1 is a radical selected from (IIa) y (IIb);
- wherein —R′ is an electron pair or a (C1-C3)-alkyl radical; with the condition that
-
- (iii) when —R′ is an electron pair, a is a N═C double bond and the
-
- fused ring
- is the biradical
- thus radicals (IIa) and (IIb) are respectively (IIa′) and (II′), and
-
- (iv) when —R′ is a (C1-C3)-alkyl radical, a is a N—C single bond and the fused ring
- is the triradical
- thus radicals (IIa) and (IIb) are respectively (IIa″) and (IIb″);
- wherein —R1 to —R12 represent radicals, same or different, selected from the group consisting of H, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylamino, phenyl, F, Cl, Br, amino, hydroxy, and nitro;
- and wherein —B— is a biradical selected from the group consisting of —CONH—,
- —NR13—, —O—, —(CH2)nNH—, —(CH2)nO—, —CONH(CH2)uZ—,
- —CONH(CH2)uCH(CH2OH)CH2Z— and —CO[NHCHR″CO]mO—; wherein —R13 is selected from the group consisting of H, (C1-C4)-alkyl, (C1-C4)-alkoxy and
- (C1-C4)-alkylamino; —R″ are side chains radicals, same or different, corresponding to natural aminoacids; n is an integer from 1 to 3; m is an integer from 1 to 3; u is an integer from 1 to 3, and —Z— is a biradical of a oligonucleotide phosphate between 4 and 23 bases in length, linked to the methylene group at the 5′ end or at the 3′ end;
- -L- is a single covalent bond or a covalent linking biradical selected from the following ones;
-
—(CH2)rNR′″(CH2)s— -
—(CH2)rNR′″(CH2)sNR″″(CH2)t— - wherein —R′″ and —R″″ are radicals, same or different, selected from the group consisting of H and (C1-C3)-alkyl; r is an integer from 1 to 3; s is an integer from 1 to 3; t is an integer from 1 to 3; and
- -G2 is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine;
- with the proviso that (I) is not one of the compounds of the following list, which have been previously described (the Chemical Abstracts Registry number, CAS RN, is given) but not for the industrial applicability of the present invention. The corresponding values for radicals in formula (I) are also included:
- 10H-quindoline-11-carboxamide (CAS RN 367911-30-6; -G1=IIa′; —B—═—CONH—; —R′=electron pair; —R1 to R8═H; -L-=single covalent bond; -G2=—H);
- 2-bromo-10H-quindoline-11-carboxamide (CAS RN 241470-56-4; -G1=IIa′; —B—═—CONH—; —R′=electron pair; —R2═—Br; —R1, —R3 to —R4, —R5 to —R8═H; -L-=single covalent bond; -G2=—H);
- N-10H-quindolin-11-yl-1,3-propanediamine (CAS RN 188630-48-0; -G1=IIa′; —B—═—NH—, —R′=electron pair; —R1 to —R4, —R5 to —R8═—H; -L-=—(CH2)3NH—; -G2=—H);
- 10H-quindolin-11-amine monohydrochloride (CAS RN 164406-49-9; G1=IIa′, —B—═—NH; —R′=electron pair; —R1 to —R4, —R5to —R8═—H; -L-=single covalent bond; -G2=—H);
- 10H-quindolin-11-methanol (CAS RN 241470-44-0; G1=IIa′; —B—═—CH2O—; —R′=electron pair; —R1 to —R4, —R5 to —R8═H, -L-=single covalent bond, -G2=—H); or
- N-[2-(dimethylamino)ethyl]-10-H-quindoline-4-carboxamide (CAS RN 191172-25-5; G1=IIb′; —B—═—CONH—; —R′=electron pair; —R1 to —R4, —R5 to —R8═—H, -L-=—(CH3)2N(CH3)CH2—, -G2=—H).
- In a preferred embodiment, compounds of formula (I) are those where (IIa) is the radical (IIa′).
- Preferred compounds are those of formula (I) where (IIa) is (IIa′) and —B— is
- —CONH— or —NR13—. Also preferred are those of formula (I) where (IIa) is (IIa′) and —B— is —CO[NHCHR″CO]mO— and more preferred are the compounds where m=2, the leftward —R″ is a glicine side chain, and the rightward —R″ is a arginine side chain . Also preferred compounds are those of formula (I) where (IIa) is (IIa′) and —B— is —CONH(CH2)uZ— or —CONH(CH2)uCH(CH2OH)CH2Z—. More preferred are the compounds where —Z— is -TTCCGGAA- linked at 3′ end or at 5′ end, or -CTTCTTCTTCT- linked at 3′ end. Specially preferred are those where -L- is a single covalent bond. Also specially preferred are those where -L- is a covalent linking biradical selected from the following ones.
-
—(CH2)rNR′″(CH2)s— -
—(CH2)rNR′″(CH2)sNR″″(CH2)t— - The most preferred are the compounds where -L- is the biradical —(CH2)rNR′″(CH2)s—, —R′″ is methyl and both r and s are 3, and the compounds where -L- is the biradical —(CH2)rNR′″(CH2)sNR″″(CH2)t—, —R′″ and —R′″ are methyl; both r and t are 2 and s is an integer from 2 to 3.
- In another preferred embodiment, compounds of formula (I) are those where (IIa) is the following radical.
- Preferred compounds are those where (IIa) is (IIa″) and —B— is —CONH— or
- —NR13—. Also preferred are those where —B— is —CO[NHCHR″CO]mO—, and more preferred are the compounds where m=2, the leftward —R″ is a glicine side chain, and the rightward —R″ is a arginine side chain. Also preferred compounds are those of formula (I) where (IIa) is (IIa″) and —B— is —CONH(CH2)uZ— or —CONH(CH2)uCH(CH2OH)CH2Z—. More preferred are the compounds where —Z— is -TTCCGGAA- linked at 3′ or 5′ end or -CTTCTTCTTCT- linked at 3′ end. Even more preferred are those where —R′ is methyl. Specially preferred are those where -L- is a single covalent bond. Also specially preferred are those where -L- is a covalent linking biradical selected from the following ones.
-
—(CH2)rNR′″(CH2)s— -
—(CH2)rNR′″(CH2)sNR″″CH2)t— - The most preferred are the compounds where -L- is the biradical —(CH2)rNR′″(CH2)s—, —R′″ is methyl and both r and s are 3, and the compounds where -L- is the biradical —(CH2)rNR′″(CH2)sNR″″(CH2)t—, —R′″ and —R′″ are methyl; both r and t are 2, and s is an integer from 2 to 3.
- The most preferred compounds of formula (I) are those of the following list, whose preparation is described in the accompanying examples for the first time: N-[3-[[3-[(9-acridinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ia); N,N′-(4-methyl-4-azaheptamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Ib);
- N-[3-[3-[[2-(1,3-dioxo-(2,3-dihydro)-1H-benzo[de]isoquinolinyl)propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ic); N-[3-[[3-[2-phenyl-4-quinolinecarbonyl)amino]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Id); N,N′-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Ie);
- N-[(9-acridinecarbonyl)-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (If); N,N′-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]quinoline-11-11′-carboxamide) (Ig); N-[(9-acridinecarbonyl)-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ih); N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[b]isoquinolyl]-3,6-dimethyl-3,6-diazaoctamethylene]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ii); N-[[1,3-dioxo-(2,3-dihydro)-1H-benzo[b]isoquinolyl]-3,7,10-triaza-3,7-dimethyldecyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ij); N,N′-(4-methyl-4-azaheptamethylene)-di-(methyl-5H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Im); 10H-indolo[3,2-b]quinoline-11-carbonyl-glicine-arginine (Io); N,N-dimethyl-N′-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-ethane-1,2-diamine (Ip); N,N′-(4-methyl-4-azaheptamethylen)-di-(10H-indolo[3,2-b]quinoline-11,11′-amine (Iq); N-1-[(5-hydroxymethyl-6-(5′-TTCCGGAA-3′-phosphate)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ir); N-1-[(5-hydroxymethyl-6-(5′-CTTCCTCCTCT-3′-phosphate)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Is); and N-1-[6-(5′-phosphate-TTCCGGAA)-hexyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (It); 10H-Indolo[3,2-b]quinoline-11-carboxylic acid(2-dimethylamino-ethyl)amide (Iu); 10H-Indolo[3,2-b]quinoline-11-carboxylic acid(2-dimethylamino-propyl)amide (Iv); N,N-dimethyl-N′-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl)-propane-1,2-diamine (Iw); N-[3-[[3-[(10H-indolo[3,2-b]quinoline-4-carboxamide]propyl]methylamino]propyl]-10H-indolo[3,2-b]quinoline-11-carboxamide (Ix); N,N′-(3,7-dimethyl-3,7-diazanonamethylene)-di-(methyl-5H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Iy); N,N′-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(methyl-5H-indolo[3,2-b]quinoline-11,11′-carboxamide) (Iz); (3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]guinoline-11,11′-carboxamide (Iaa); N,N′-(3,7-dimethyl-3,7-diazanonamethylene)-di-(10H-indolo[3,2-b]guinoline-11,11′-amine (lab); N,N′-(3,6-dimethyl-3,6-diazaoctamethylene)-di-(10H-indolo[3,2-b]guinoline-11,11′-amine (lac).
- Another aspect of the present invention refers to the use of the compound of formula (I), defined above, for the preparation of a medicament for the treatment of cancer.
- A further aspect of the present invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of formula (I), defined above, together with suitable pharmaceuticalexcipients or carriers.
- Compounds of formula (I) where biradical —B— in -G1 is —CONH— and -G2 is not the N-radical of 1,8-naphtalimide can be prepared according to the process summarized in Scheme I, where GP represents an amino protecting group. The process involves a coupling reaction of a compound of formula (Vb) with a compound of formula (III). The compound of formula (Vb) is prepared by reaction of a compound of formula (III) with a monoprotected bis-amine of formula (IV), followed by the removal of the amino protective group. Monoprotected bis-amines of formula (IV) are commercially available compounds or they can be prepared by methods known in the art (cf. Spicer et al., Bioorg. Med. Chem. 2002, vol. 10, p. 19; Deady et al., Bioorg. Med. Chem. 2000, vol. 8, p. 977). An example of amino protective group is the t-butoxycarbonyl (BOC).
- When biradical —B— in -G1 is —CONH— and -G2 is 1,8-naphthalamide, compounds of formula (I) can be obtained by the process summarized in Scheme II. This process involves the coupling reaction of a compound of formula (VIIb) with a compound of formula (III). The compound of formula (VIIb) can be prepared by reaction of 1,8-naphthalic anhydride (VI) with a monoprotected bis-amine of formula (IV), followed by the removal of the amino protective group.
- Compounds of formula (I) where —B— is a biradical selected from other groups as —NR13—, —O—, —(CH2)nNH—, —(CH2)nO—, can be obtained analogously by using standards processes of organic chemistry, well known in the art for the production of such type of compounds. For example, for —B—═—NH— the process of Scheme III can be followed, as it has been done for the compound of the Example 15.
- Compounds of formula (I) where biradical —B— is —CO[NHCHR″CO]mO—, —R″ is side chain radicals, same or different, corresponding to a natural aminoacid and m is an integer selected from 1 to 3, can be obtained by solid phase methods. The synthesis is carried out assembling a N-protected aminoacid or peptide in a p-methylbenzhydrilamine resine. After removal of the protective group, the 11-aminocarboxylic radical selected from formula (IIa) or the 4-aminocarboxylic radical selected from formula (IIb) is coupled by benzotriazol-1-yloxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and diisopropylamine, followed by acidolysis.
- Compounds of formula (I) where —B— is a birradical selected from —CONH(CH2)uZ— or —CONH(CH2)uCH(CH2OH)CH2Z—, where u is an integer from 1 to 6, and —Z— is a biradical of a oligonucleotide phosphate between 4 and 23 bases in length, linked to the methylene group at 5′ end or at 3′ end can be prepared by conventional methods of peptide coupling in solid phase or solution phase.
- Compounds of formula (I) may be converted into pharmaceutically acceptable acid addition salts, and salts may be converted into free compounds, by conventional methods. For instance, the acid addition salts may be prepared by contacting the free base with an appropriate amount of the desired acid in a conventional manner.
- Compounds of formula (I) are intercalators (i.e. compounds which intercalate between DNA base pairs) and, as illustrated by biological results in example 30 are active for cancer treatment.
- Throughout the description and claims the word “comprise” and variations of the word, are not intended to exclude other technical features, additives, components, or steps. The abstract of this application is incorporated herein as reference. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid previously prepared (cf. Bierer et al., J. Med. Chem. 1998, vol. 41, p. 894 (0.2 g, 0.76 mmol) was dissolved in 5 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 5 ml of CH2Cl2. A solution of [3-[(3-aminopropyl)methylamino]propyl]carbamic acid tert-butyl ester previously prepared (Spicer at el., Bioorg. Med. Chem. 2002, vol. 10, p. 19) (0.26 g, 1.1 mmol) and triethylamine (0.4 ml) in 5 ml of CH2Cl2 was added at room temperature, and the mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 90:10) yielded [2-[[2-[(10H-Indolo[3,2-b]quinoline-11-carbonyl)amino]ethyl]methylamino)ethyl]carbamic acid tert-butyl ester (0.26 g, 70%) as a viscous oil. 1H-NMR [MeOD, δ, ppm]: 8.48 (d, J=7.8 Hz, 1H), 7.25 (m, 2H), 7.64 (m, 4H), 7.35 (dd, J=8.0 Hz, 1H), 3.67 (t, J=6.9 Hz, 2H, CH2NO), 3.07 (t, J=6.9 Hz, 2H, CH2NHBOC), 2.56 (m, 2H, CH2N(CH3)), 2.43 (m, 2H, CH2N(CH3)), 2.26 (s, 3H, N(CH3)), 1.66 (m, 4H, 2CH2CN(CH3)), 1.48 (s, 9H, C(CH3)3).
- To a solution of [2-[[2-[(10H-indolo[3,2-b]quinoline-11-carbonyl)amino]-ethyl]methylamino)ethyl]-carbamic acid tert-butyl ester (0.13 g, 0.27 mmol) in CH2Cl2 (15 ml), was added trifluoroacetic acid (3 ml). The reaction mixture was stirred at room temperature for 16 h at which point the reaction was completed by TLC. All solvents were removed under reduced pressure to give 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methylamino]propyl]-11-carboxamide (0.09 g, 92%) as an oil, which was used directly in the next reaction. 1H-NMR [MeOD, δ, ppm]: 8.51 (d, J=7.8 Hz, 1H), 8.32 (m, 2H), 8.02 (m, 1H), 7.84 (m, 2H), 7.67 (d, J=8.0 Hz, 1H), 7.44 (m, 1H), 3.76 (t, J=6.9 Hz, 2H, CH2NO), 3.31 (m, 2H, CH2NH2), 2.96 (s, 3H, N(CH3)), 2.27 (m, 2H, CH2N(CH3)), 2.15 (m, 2H, CH2N(CH3)), 1.26 (m, 4H, 2CH2CN(CH3)).
- 9-acridinecarboxylic acid (0.036 g, 0.16 mmol) was dissolved in 3 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 4 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methyl-amino]propyl]-11-carboxamide (0.076 g, 0.19 mmol) and triethylamine (0.2 ml) in 4 ml of CH2Cl2 was added at room temperature, and the reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (55 mg, 50%) as a solid. mp 108-110° C. 1H-NMR [CDCl3, δ, ppm]: 8.38 (m, 1H), 8.05 (m, 7H), 7.58 (m, 7H), 7.26 (m, 1H), 3.59 (m, 4H, 2CH2NO), 2.55 (m, 4H, 2CH2NO), 2.26 (s, 3H, N(CH3)), 1.91 (m, 4H, 2CH2CN(CH3)); MS (EI, m/z) 595 (M++1).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.02 g, 0.08 mmol) was dissolved in 2 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methylamino]propyl]-11-carboxamide (0.037 g, 0.09 mmol) prepared as in Example 1, and triethylamine (0.2 ml) in 2 ml of CH2Cl2 was added at room temperature, and the mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (30 mg, 50%) as a solid. mp 124-126° C. 1H NMR [CDCl3, δ, ppm]: 8.47 (m, 2H), 8.17 (m, 4H), 7.59 (m, 8H), 7.25 (m, 2H), 3.65 (m, 4H, 2CH2NO), 2.63 (m, 4H, 2CH2NO), 2.33 (s, 3H, N(CH3)), 1.99 (m, 4H, 2CH2CN(CH3)); MS (EI, m/z) 634 (M++1).
- 1,8-naphthalic anhydride (0.18 g, 0.9 mmol) was added to a solution of [3-[(3-aminopropyl)methylamino]propyl]carbamic acid tert-butyl ester previously prepared (Spicer at el., Bioorg. Med. Chem. 2002, vol. 10, p. 19) (0.2 g, 0.8 mmol) in absolute ethanol (20 ml). The reaction mixture was heated at reflux overnight. Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 50:1) yielded [3-[[3-(1,3-dioxo-3a,9b-dihydro-1H,3H-benzo[de]isoquinolin-2-yl)propyl]methylamino]propyl]carbamic acid tert-butyl ester (0.37 g, 90%) as a foam. 1H-NMR [CDCl3, δ, ppm]: 8.62 (m, 2H), 8.22 (m, 2H), 7.72 (m, 2H), 4.23 (m, 2H, 2CH2NO), 3.20 (m, 2H, CH2NH), 2.55 (m, 4H, 2(CH2)), 2.26 (s, 3H, N(CH3)), 1.93 (m, 2H, (CH2)), 1.68 (m, 2H, (CH2)), 1.48 (s, 9H, C(CH3)3).
- To a solution of [3-[[3-(1,3-dioxo-3a,9b-dihydro-1H,3H-benzo[de]isoquinolin-2-yl)propyl]methylamino]propyl]carbamic acid tert-butyl ester (0.34 g, 0.81 mmol) in CH2Cl2 (24 ml) was added trifluoroacetic acid (6 ml). The reaction mixture was stirred at room temperature for 16 h at which point the reaction was completed by TLC. All solvents were removed under reduced pressure to give 2-[3-[(3-aminopropyl)methylamino]propyl]-3a,9b-dihydro-benzo[de]isoquinoline-1,3-dione (0.24 g, 92%) as an oil, which was used directly in the next reaction. 1H-NMR [MeOD, δ, ppm]: 8.64 (m, 2H), 8.54 (m, 2H), 7.92 (m, 2H), 4.45 (m, 2H, 2CH2NO), 3.55 (m, 4H, 2CH2), 3.33 (m, 2H, CH2), 3.22 (s, 3H, N(CH3)), 2.44 (m, 4H, 2(CH2)).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.24 g, 0.9 mmol) was dissolved in 7 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 10 ml of CH2Cl2. A solution of 2-[3-[(3-aminopropyl)methyl-amino]propyl]-3a,9b-dihydro-benzo[de]isoquinoline-1,3-dione (0.24 g, 0.73 mmol) and NEt3 (1 ml) in 10 ml of CH2Cl2 was added at room temperature, and the reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (0.13 g, 30%) as a solid. mp 200-204° C. 1H-NMR [CDCl3, δ, ppm]: 8.38-8.02 (m, 7H), 7.61-7.37 (m, 7H), 3.86 (m, 4H, 2CH2NO), 2.60 and 2.40 (m, 4H, 2CH2NO), 2.22 (s, 3H, N(CH3)), 1.91 and 1.61 (m, 4H, 2CH2CN(CH3)).
- Activation and coupling of 10H-indolo[3,2-b]quinoline-11-carboxylic acid with 2-phenyl-quinoline-[3-[(3-aminopropyl)methylamino]propyl]-4-carboxamide (prepared analogously to Example 1 from 2-phenyl-4-quinolinecarboxylic acid), gave the desired compound as a solid, 36%, mp 144-148° C. 1H-NMR [MeOD, δ, ppm]: 8.18 (m, 2H), 8.08 (m, 4H), 7.61-7.44 (m, 10H), 7.28 (m, 1H), 3.68 (m, 2H, 2CH2NO), 3.54 (m, 2H, 2CH2NO), 3.34 (s, 3H, N(CH3)), 2.64 (m, 4H, 2CH2CN(CH3)); 1.98 (m, 4H, 2CH2); MS (EI, m/z) 619 (M+−1).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.25 g, 0.95 mmol) was dissolved in 5 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 5 ml of CH2Cl2. A solution of [2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]carbamic acid tert-butyl ester (Deady et al., Bioorg. Med. Chem. 2000, vol. 8, p. 977) (0.38 g, 1.3 mmol) and triethylamine (0.4 ml) in 5 ml of CH2Cl2 was added at room temperature. The reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 90:10) yielded [2-[[3-[[2-[(10H-indolo[3,2-b]quinoline-11-carbonyl)-amino]ethyl]methylamino]propyl]methyl-amino]ethyl]carbamic acid tert-butyl ester (0.31 g, 62%) as a viscous oil . 1H-NMR [CDCl3, δ, ppm]: 8.45 (d, J=7.8 Hz, 1H), 8.25 (m, 2H), 7.62 (m, 4H), 7.35 (dd, J=8.0, 8.0 Hz, 1H), 3.85 (m, 2H, CH2NO), 3.21 (m, 2H, CH2), 3.07 (m, 2H, CH2NHBOC), 2.79 (m, 4H, 2CH2N(CH3)), 2.37-2.19 (m, 4H, 2(CH2)), 2.15 (s, 6H, 2N(CH3)), 1.48 (s, 9H, C(CH3)3).
- To a solution [2-[[3-[[2-[(10H-indolo[3,2-b]quinoline-11-carbonyl)amino]ethyl]methylamino]propyl]methylamino]ethyl]carbamic acid tert-butyl ester (0.3 g, 0.57 mmol) in CH2Cl2 (20 ml), was added trifluoroacetic acid (6 ml). The reaction mixture was stirred at room temperature for 16 h, at which point the reaction was completed by TLC. All solvents were removed under reduced pressure to give 10H-indolo[3,2-b]quinoline-[2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]-11-carboxamide (0.23 g, 92%) as a oil, which was used directly. 1H-NMR [MeOD, δ, ppm]: 8.59 (d, J=7.8 Hz, 1H), 8.44 (m, 2H), 8.09 (m,1H), 7.94 (m, 2H), 7.87 (d, J=8.0 Hz, 1H), 7.51 (m, 1H), 3.68 (m, 2H, CH2NO), 3.46 (m, 8H, 4CH2), 3.11 (m, 4H, 2CH2N(CH3)), 2.97 (s, 6H, 2N(CH3)).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.11 g, 0.41 mmol) was dissolved in 10 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 15 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-11-carboxylic acid[2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]-ethyl]-amide (0.23 g, 0.5 mmol) and triethylamine (0.5 ml) in 15 ml of CH2Cl2 was added at room temperature. The reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (0.14 g, 52%) as a foam. 1H-NMR [CDCl3, δ, ppm]: 8.48 (m, 2H), 8.30 (m, 4H), 7.73-7.54 (m, 8H), 7.25 (m, 2H) 3.77 (m, 4H, 2CH2NO), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 6H, 4CH2), 2.15 (s, 6H, 2N(CH3)).
- 9-acridinecarboxylic acid (0.15 g, 0.67 mmol) was dissolved in 15 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 15 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-[2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]-11-carboxamide (0.4 g, 0.92 mmol) and triethylamine (1 ml) in 15 ml of CH2Cl2 was added at room temperature. The reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (0.38 g, 88%) as a foam. 1H-NMR [CDCl3, δ, ppm]: 8.12 (m, 1H), 8.02 (m, 7H), 7.58 (m, 7H), 7.33 (m, 1H), 3.77 (m, 4H, 2CH2NO), 2.58 (m, 4H, 2CH2N(CH3)), 2.48 (m, 6H, 4CH2), 2.28 (s, 6H, 2N(CH3)).
- Activation and coupling of 10H-indolo[3,2-b]quinoline-11-carboxylic acid with 10H-indolo[3,2-b]quinoline-[2-[[2-[(2-aminoethyl)methylamino]-ethyl]-methylamino]thyl]-11-carboxamide (prepared analogously to Example 5 from [2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]carbamic acid tert-butyl ester) gave the desired compound as a foam, 38%. 1H-NMR [CDCl3, δ, ppm]: 8.46 (m, 2H), 8.30 (m, 4H), 7.73-7.54 (m, 8H), 7.18 (m, 2H) 3.62 (m, 4H, 2CH2NO), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 4H, 4CH2), 2.35 (s, 6H, 2N(CH3)).
- Activation and coupling of 9-acridinecarboxylic acid with 10H-indolo[3,2-b]quinoline-[2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]-11-carboxamide (prepared analogously to Example 5 from [2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]carbamic acid tert-butyl ester) gave the desired compound as a foam, 48%. 1H-NMR [CDCl3, δ, ppm]: 8.12 (m, 1H), 8.02 (m, 7H), 7.58 (m, 7H), 7.33 (m, 1H), 4.02 (m, 4H, 2CH2NO), 3.98 (m, 4H, 2CH2N(CH3)), 3.01 (m, 4H, 4CH2), 2.70 (s, 6H, 2N(CH3)).
- Activation and coupling of 10H-indolo[3,2-b]quinoline-11-carboxylic acid with 2-[2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]-benzo[de]isoquinoline-1,3-dione (prepared analogously to Example 3 from 2-[[2-[(2-amino-ethyl)methylamino]ethyl]methylamino]ethyl]carbamic acid tert-butyl ester) gave the desired compound as a foam, 37%, 1H-NMR [CDCl3, δ, ppm]: 8.55-8.11 (m, 7H), 7.72-7.17 (m, 7H), 4.03 (m, 4H, 2CH2NO), 3.80 (m, 4H, 2CH2N(CH3)), 2.93-2.64 (m, 4H, 4CH2), 2.55 (s, 6H, 2N(CH3)).
- Activation and coupling of 10H-indolo[3,2-b]quinoline-11-carboxylic acid with 2-[2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]-benzo[de]isoquinoline-1,3-dione (prepared analogously to Example 3 from 2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]carbamic acid tert-butyl ester) gave the desired compound as a foam, 40%. 1H-NMR [CDCl3 δ, ppm]: 8.59-8.02 (m, 7H), 7.77-7.25 (m, 7H), 4.05 (m, 4H, 2CH2NO), 3.82 (m, 4H, 2CH2N(CH3)), 2.78-2.34 (m, 6H, 4CH2), 2.25 (s, 6H, 2N(CH3)).
- The 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid is known in the literature as part of extract plant Cryptolepis sanguinolenta (cf. Paulo et al., Planta Medica 2000, vol. 66, p. 30). It can also be prepared by the following process:
- 5,11-dimethyl-5H-indolo[3,2-b]quinoline (cf. Yang et al., J. Nat. Prod, 1999, vol. 62, pp. 976] (0.1 g, 0.4 mmol) was added to 10 ml of water. KMnO4 (64 mg. 0.4 mmol) is added, and the solution is heated to reflux for 1 h. Then a second portion of KMnO4 (64 mg. 0.4 mmol) is introduced, followed by 10 ml of water, and the heating is continued for 1 h. The reaction mixture is allowed to cool slightly, and the precipitated oxide of manganese is filtered and washed with hot water. The filtrated is concentrated under reduced pressure to half of the volume, filtered and acidified with concentrated hydrochloric acid. This acid solution is then evaporated to dryness under reduced pressure to give the desired compound (70 mg, 64%), which was used directly. 1H-NMR [MeOD δ, ppm]: 8.24 (m, 2H), 7.79 (m, 2H), 7.54 (m, 4H), 5.15 (s, 3H) MS (EI, m/z) 277 (M++1).
- Activation and coupling of 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid, prepared as in Example 11, with 5-methyl-5H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methylamino]propyl]-11carboxamide (prepared analogously to Example 1 from 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid) gave the desired compound as a foam, 50%, 1H NMR [CDCl3 δ, ppm]: 8.47 (m, 2H), 8.17 (m, 4H), 7.59 (m, 8H), 7.25 (m, 2H), 5.15 (s, 6H), 3.65 (m, 4H, 2CH2NO), 2.63 (m, 4H, 2CH2NO), 2.33 (s, 3H, N(CH3)), 1.99 (m, 4H, 2CH2CN(CH3)).
- The compound of the title was prepared by solid phase methods. After assembling the Boc-glicine-arginine sequence on a p-methylbenzhydrylamine resin, the N-terminal was deprotected and 10H-indolo[3,2-b]quinoline-11-carboxylic acid was coupled by means of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluoro-phosphate (PyBOP) and diisopropylethylamine (5, 5 and 10 equivalents, respectively) in 1:1 DMSO-DMF for 1 h. Acidolysis with HF/anisole (9:1, 0° C., 1 h) provided the desired compound in highly homogeneous form (>98% by HPLC). MS(MALDI-TOF): EM(expected): 474.1; EM(found): 475.5 (M+H+).
- A solution of 11-cloro-5-metil-5H-indolo[3,2-b]quinoline previously prepared (cf. Bierer et al., J. Med. Chem. 1998, vol. 41, p. 2754) (66 mg, 0.25 mmol) and N,N-dimethylethylenediamine (94 μl, 1 mmol) in 2-ethoxyethanol (10 ml) was heated at 120° C. for 10 min. Removal of the solvent and chromatography on alumina (CHCl3 100%) yielded the desired compound (36 mg, 46%) as a yellow solid. m. p. 162-164° C. 1H NMR [CDCl3 δ, ppm]: 8.28 (d, J=8.5 Hz, 1H), 7.89 (m, 2H), 7.69-7.61 (m, 3H), 7.31 (m, 2H), 4.58 (s, 3H, NCH3), 4.32 (m, 2H, CH2), 3.14 (m, 2H, CH2), 2.51 (s, 6H, N(CH3)2).
- A solution of 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline (cf. Bierer et al., J. Med. Chem. 1998, vol. 41, pp. 2754) (61 mg, 0.23 mmol) and [[3-[(3-amino-propyl)methylamino]propyl]carbamic acid tert-butyl ester previously prepared (Spicer at el., Bioorg. Med. Chem. 2002, vol. 10, p. 19) (84 μl, 0.34 mmol) in 2-ethoxyethanol (10 ml) was heated at 120° C. for 10 min. Removal of the solvent and purification by chromatography on alumina (CHCl3: MeOH 2%) yielded [3-[methyl-[3-(5-methyl-5H-indolo[3,2-b]quinolin-11-yl-amino)propyl]-amino]propyl]carbamic acid tert-butyl ester (49 mg, 49%) as a foam. 1H NMR [CDCl3 δ, ppm]: 8.16 (d, J=8.5 Hz, 1H), 7.81 (m, 4H), 7.55-7.48 (m, 2H), 7.21 (m, 1H), 4.51 (s, 3H, NCH3), 4.27 (m, 2H, CH2NO), 3.12 (m, 2H, CH2NHBOC), 2.76 (m, 2H, CH2N(CH3)), 2.63 (m, 2H, CH2N(CH3)), 2.39 (s, 3H, N(CH3)), 2.34 (m, 2H, CH2CN(CH3)), 1.73 (m, 2H, CH2CN(CH3)), 1.37 (s, 9H, C(CH3)3).
- To a solution of [3-[methyl-[3-(5-methyl-5H-indolo[3,2-b]quinolin-11-ylamino)-propyl]amino]propyl]-carbamic acid tert-butyl ester (49 mg, 0.1 mmol) in CH2Cl2 (10 ml), was added trifluoroacetic acid (12 μl). This mixture was stirred at room temperature for 16 h, at which point the reaction was completed by TLC. All solvents were removed under reduced pressure to give N1-methyl-N1-[3-(5-methyl-5H-indolo[3,2-b]quinolin-11-ylamino)propyl]propane-1,3-diamine (38 mg, 92%) as an oil, which was used directly. 1H-NMR [MeOD, δ, ppm]: 8.52 (d, J=8.5 Hz, 1H), 8.35-7.73 (m, 4H), 7.63-7.60 (m, 2H), 7.31 (m, 1H), 4.45 (s, 3H, NCH3), 3.60 (m, 2H, CH2NO), 3.02 (m, 2H, CH2N(CH3)), 2.92 (s, 3H, N(CH3)), 2.36 (m, 4H, 2CH2CN(CH3)), 2.14 (m, 2H, CH2N(CH3)), 1.90 (m, 2H, CH2CN(CH3)).
- A solution of 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline, previously prepared, (cf. Bierer et al., J. Med. Chem. 1998, vol. 41, p. 2754) (40 mg, 0.15 mmol) and N1-methyl-N1-[3-(5-methyl-5H-indolo[3,2-b]quinolin-11-ylamino)-propyl]propane-1,3-diamine (38 mg, 0.1 mmol) in 2-ethoxyethanol (10 ml) was heated at 120° C. for 10 min. Removal of the solvent and purification by chromatography on alumina (CHCl3 100%) yielded the desired compound (17 mg, 46%) as a foam. 1H NMR [CDCl3 δ, ppm]: 8.16-8.21 (m, 4H), 8.01 (m, 2H), 7.93-7.71 (m, 4H), 7.50-7.30 (m, 2H), 7.23-7.25 (m, 4H), 4.26 (s, 3H, NCH3), 4.24 (s, 3H, NCH3), 4.12 (m, 2H, CH2NO), 3.03 (m, 2H, CH2), 2.80 (m, 2H, CH2N(CH3)), 2.70 (m, 2H, CH2N(CH3)), 2.44 (s, 3H, N(CH3)), 2.16 (m, 2H, CH2CN(CH3)), 1.72 (m, 2H, CH2CN(CH3)).
- 5′TTCCGGAA-NH2-3′ oligonucleotide sequence carrying an amino group at the 3′ end was prepared using 3-O-dimethoxytrityloxy-2-(N-9-fluorenphenylmethoxycarbonyl-4-aminobutyl)-1-propanyl ester succinamidyl-controlled pore glass (3′ amino C7 modifier CPG from Glen Research). The solid support obtained after the assembly of the sequence was treated with a 0.1 M solution of 1,8-diazabiciclo[5.4.0]undece-7-ene (DBU) in dry acetonitrile (2 min, room temperature). In this way, the Fmoc group that protects the amino group is removed selectively with a non-nucleophillic base. The resulting support was washed with acetonitrile and reacted with 10H-indolo[3,2-b]quinoline-11-carboxylic acid as follows. A mixture containing 10 molar excess of 10H-indolo[3,2-b]quinoline-11-carboxylic acid, 20 molar excess of diisopropylethylamine (DIEA) as base catalyst and 10 molar excess of (benzotriazol-1-yloxy)trispyrrolidinophosphonium hexafluorophosphate (PyBOP) as carboxyl activator was prepared in dry dimethylformamide (DMF) (0.2 ml). The mixture was left for 2 min at room temperature and added to the support. After 1 hour at room temperature, the mixture was filtered and washed with DMF. The support was dried and concentrated ammonia (1 ml) was added. The ammonia solution was left for 1 hr at 50° C. The mixture was filtered and the ammonia solution was concentrated to dryness. The residue was dissolved in water and desalted by NAP-10 (Sephadex G-25) eluted with water. Finally, the oligonucleotide fractions were analyzed by HPLC. HPLC solutions were as follows. Solvent A: 5% ACN in 100 mM triethylammonium acetate pH 6.5 and solvent B: 70% ACN in 100 mM triethylammonium acetate pH 6.5. Columns: PRP-1 (Hamilton), 250×10 mm. Flow rate: 3 ml/min. A 20 min linear gradient from 5-35%. The compound of the title eluted at 14.0 min. Unreacted amino-oligonucleotide eluted around 9 min. The desired product was characterized by the UV-spectra. UVmax: 258,348. Yield: 7%.
- 5′TTCCGGAA-NH2 3′ oligonucleotide sequence carrying an amino group at the 3′ end was prepared using the 3′ amino C7 modifier CPG (Glen Research). The solid support obtained after the assembly of the sequence was treated with concentrated ammonia for 1 hr at 50° C. The mixture was filtered and the ammonia solution was concentrated to dryness. The residue was passed over a Dowex 50×4 (Na+ form) column to exchange ammonium ions for sodium ions. The resulting amino-oligonucleotide was dissolved in 0.1 ml of water, and mixed with 0.1 ml of 1M sodium carbonate aqueous buffer pH 8-9. In a separate container 10H-indolo[3,2-b]quinoline-11-carboxylic acid (10 molar excess) was dissolved in 0.1 ml of DMF, and mixed with N-hydroxysuccinimide (10 molar excess) and N,N-diisopropylcarbodiimide (10 molar excess). The mixture was left for 10 min at room temperature and added to the aqueous solution of the amino-oligonucleotide. The reaction mixture was kept at room temperature overnight. The mixture was concentrated to dryness and the residue was dissolved in water. The solution was passed through a NAP-10 column. The fractions containing oligonucleotide were analyzed by HPLC. HPLC solutions were as follows: Solvent A: 5% ACN in 100 mM triethylammonium acetate pH 6.5 and solvent B: 70% ACN in 100 mM triethylammonium acetate pH 6.5. Columns: PRP-1 (Hamilton), 250×10 mm. Flow rate: 3 ml/min. A 20 min linear gradient from 5-35%. The compound of the title eluted at 14.0 min Unreacted amino-oligonucleotide eluted around 9 min. The desired product was characterized by the UV-spectra. UVmax: 258, 348 and mass spectrometry (MALDI-TOF): found 2861 (M+H+) expected 2862. Yield: 18%.
- The compound of the title was obtained in a similar way to example 16 but ammonia treatment was run for 2 hours at room temperature. The compound of the title eluted at 13.8 min. It was characterized by the UV-spectra. UVmax: 273, 349. Yield: 5%.
- The compound of the title was obtained in a similar way to example 17. The compound of the title eluted at 13.9 min. It was characterized by the UV-spectra. UVmax: 273, 349, and mass spectrometry (MALDI-TOF): found 3646 (M+H+) expected 3647. Yield: 20%.
- 5′NH2-TTCCGGAA 3′ oligonucleotide sequence carrying an amino group at the 5′ end was prepared using the phosphoramidite of the N6-monomethoxytrityl (MMT) protected derivative of 6-aminohexanol (Glen Research). The solid support obtained after the assembly of the sequence was treated with concentrated ammonia for 1 hr at 50° C. Reaction of the 5′ amino-oligonucleotide with 10H-indolo[3,2-b]quinoline-11-carboxylic acid was carried out as described in example 17. The compound of the title eluted at 16 min. The desired product was characterized by the UV-spectra UVmax: 268, 349. Yield: 12%.
- 10H-Indolo[3,2-b]quinoline-11-carboxylic acid (0.5 g, 1.9 mmol) was dissolved in 20 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 10 ml of CH2Cl2. A solution of N,N-dimethylethylendiamine (0.2 mL, 2.26 mmol) and triethylamine (2.2 ml) in 10 ml of CH2Cl2 was added at room temperature, and the mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 90:10) yielded the desired compound (0.38 g, 61%) as a solid. m. p. 175-176° C. 1H-NMR [MeOD, δ, ppm]: 8.16 (d, J=7.8 Hz, 1H), 7.92 (m, 2H), 7.35-7.20 (m, 3H), 7.04 (m, 2H), 3.62 (m, 2H, CH2NO), 2.55 (m, 2H, CH2N(CH3)2), 2.29 (s, 6H, N(CH3)2). MS (EI, m/z) 277 (M++1).
- 10H-Indolo[3,2-b]quinoline-11-carboxylic acid (0.2 g, 0.76 mmol) was dissolved in 8 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 10 ml of CH2Cl2. A solution of N,N-dimethylproylendiamine (0.1 mL, 0.97 mmol) and triethylamine (1 ml) in 10 ml of CH2Cl2 was added at room temperature, and the mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 90:10) yielded the desired compound (80 mg, 31%) as a solid. m. p. 188-189° C. 1H-NMR [MeOD, δ, ppm]: 8.16 (d, J=7.8 Hz, 1H), 7.92 (m, 2H), 7.35-7.20 (m, 3H), 7.04 (m, 2H), 3.62 (m, 2H, CH2NO), 2.55 (m, 2H, CH2N(CH3)2), 2.29 (s, 6H, N(CH3)2), 1.88 (m, 2H, CH2). MS (EI, m/z) 347 (M++1).
- A solution of 11-chloro-5-metil-5H-indolo[3,2-b]quinoline (47 mg, 0.17 mmol) and N,N-dimethylpropylenediamine (78 μl, 0.76 mmol) in 2-ethoxyethanol (5 ml) was heated at 120° C. for 10 min. Removal of the solvent and chromatography on alumina (CHCl3 100%) yielded the desired compound (20 mg, 35%) as a foam. 1H NMR [CDCl3 δ, ppm]: 8.28 (d, J=8.5 Hz, 1H), 7.89 (m, 2H), 7.69-7.61 (m, 3H), 7.31 (m, 2H), 4.58 (s, 3H, NCH3), 4.23 (m, 2H, CH2), 3.86 (m, 2H, CH2), 3.55 (m, 2H, CH2), 2.55 (s, 6H, N(CH3)2). MS (EI, m/z) 333 (M++1).
- 10H-indolo[3,2-b]quinoline-4-carboxylic acid (0.2 g, 0.76 mmol) was dissolved in 5 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 5 ml of CH2Cl2. A solution of [3-[(3-aminopropyl)methylamino]propyl]carbamic acid tert-butyl ester (0.26 g, 1.1 mmol) and triethylamine (0.4 ml) in 5 ml of CH2Cl2 was added at room temperature, and the mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine, HCl 1N) and dried (MgSO4). All solvents were removed under reduced pressure to give 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methylamino]propyl]-4-carboxamide (0.14 g, 48%) as an oil, which was used directly in the next reaction. 1H-NMR [MeOD, δ, ppm]: 8.72 (d, J=7.8 Hz, 1H), 8.63 (d, J=7.8 Hz, 1H), 8.51 (d, J=7.8 Hz, 1H), 7.97 (m, 2H), 7.79 (d, J=8.0 Hz, 1H), 7.43 (m, 2H), 3.75 (t, J=6.9 Hz, 2H, CH2NO), 3.31 (m, 2H, CH2NH2), 2.96 (s, 3H, N(CH3)), 2.27 (m, 2H, CH2N(CH3)), 2.15 (m, 2H, CH2N(CH3)), 1.35 (m, 4H, 2CH2CN(CH3)).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.066 g, 0.25 mmol) was dissolved in 3 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-[3-[(3-aminopropyl)methyl-amino]propyl]-4-carboxamide (0.14 g, 0.36 mmol) and triethylamine (0.2 ml) in 2 ml of CH2Cl2 was added at room temperature, and the reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (27 mg, 17%) as an oil. 1H-NMR [CDCl3, 6, ppm]: 8.43 (m, 1H), 8.28 (m, 7H), 7.58 (m, 7H), 7.26 (m, 1H), 3.20 (m, 4H, 2CH2NO), 2.49 (m, 4H, 2CH2NO), 2.05 (s, 3H, N(CH3)), 1.64 (m, 4H, 2CH2CN(CH3)).
- Activation and coupling of 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid with 5-methyl-5H-indolo[3,2-b]quinoline[2-[[2-[(2-aminoethyl)methylamino]-ethyl]-methylamino]ethyl]-11-carboxamide (prepared analogously to Example 5 from [2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]carbamic acid tert-butyl ester and 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid gave the desired compound as a foam, (4 mg, 15%), 1H NMR [CDCl3 δ, ppm]: 8.47 (m, 2H), 8.17 (m, 4H), 7.59 (m, 8H), 7.25 (m, 2H), 5.15 (s, 6H), 3.77 (m, 4H, 2CH2NO), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 6H, 4CH2), 2.15 (s, 6H, 2N(CH3)).
- Activation and coupling of 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid with 5-methyl-5H-indolo[3,2-b]quinoline[2-[[2-[(2-aminoethyl)methylamino]-ethyl]-methyl-amino]ethyl]-11-carboxamide (prepared analogously to Example 7 from [2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]carbamic acid tert-butyl ester and 5-methyl-5H-indolo[3,2-b]quinoline-11-carboxylic acid gave the desired compound as a foam, (28 mg, 10%), 1H NMR [CDCl3 δ, ppm]: 8.47 (m, 2H), 8.17 (m, 4H), 7.59 (m, 8H), 7.25 (m, 2H), 5.15 (s, 6H), 3.65 (m, 4H, 2CH2NO), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 4H, 4CH2), 2.35 (s, 6H, 2N(CH3)).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.056 g, 0.21 mmol) was dissolved in 2 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH2Cl2. A solution of (2-[3-(2-amino-ethylamino]-ethyl)-carbamic acid tert-butyl ester (0.079 g, 0.3 mmol) and triethylamine (0.2 ml) in 2 ml of CH2Cl2 was added at room temperature. The reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 90:10) yielded [2-(3-{2-[10H-indolo[3,2-b]quinoline-11-carbonyl)-amino]-ethylamino}-propylamino)-ethyl]carbamic acid tert-butyl ester (0.025 g, 25%) as a viscous oil . 1H-NMR [CDCl3, δ, ppm]: 8.46 (d, J=7.8 Hz, 1H), 8.30 (m, 2H), 7.68 (m, 4H), 7.53 (dd, J=8.0, 8.0 Hz, 1H), 3.65 (m, 2H, CH2NO), 3.12 (m, 2H, CH2), 3.07 (m, 2H, CH2NHBOC), 2.06 (m, 4H, 2CH2NH), 1.67-1.55 (m, 4H, 2(CH2)), 1.48 (s, 9H, C(CH3)3).
- To a solution [2-(3-{2-[10H-indolo[3,2-b]quinoline-11-carbonyl)-amino]-ethylamino}-propylamino)-ethyl]carbamic acid tert-butyl ester (0.025 g, 0.049 mmol) in CH2Cl2 (5 ml), was added trifluoroacetic acid (1 ml). The reaction mixture was stirred at room temperature for 16 h, at which point the reaction was completed by TLC. All solvents were removed under reduced pressure to give 10H-indolo[3,2-b]quinoline-11-carboxylic acid(2-[3-(2-amino-ethylamino)-propylamino]-ethyl]-amide (0.02 g , 95%) as a oil, which was used directly. 1H-NMR [MeOD, δ, ppm]: 8.55 (d, J=7.8 Hz, 1H), 8.26 (m, 2H), 8.00 (m,1H), 7.80 (m, 2H), 7.64 (d, J=8.0 Hz, 1H), 7.26 (m, 1H), 4.19 (m, 2H, CH2NO), 3.56 (m, 8H, 4CH2), 3.20 (m, 4H, 2CH2NH).
- 10H-indolo[3,2-b]quinoline-11-carboxylic acid (0.009 g, 0.034 mmol) was dissolved in 2 ml of refluxing SOCl2. After 6 hours a clear solution was obtained, and all volatiles were removed in vacuo. The crude acid chloride was suspended in 2 ml of CH2Cl2. A solution of 10H-indolo[3,2-b]quinoline-11-carboxylic acid(2-[3-(2-amino-ethylamino)-propylamino]-ethyl]-amide (0.02 g, 0.049 mmol) and triethylamine (0.2 ml) in 2 ml of CH2Cl2 was added at room temperature. The reaction mixture was stirred for 14 hours. The organic phase was washed (NaHCO3, brine) and dried (MgSO4). Removal of the solvent and purification by chromatography on alumina (CH2Cl2/MeOH, 95:5) yielded the desired compound (0.015 g, 68%) as a foam. 1H-NMR [CDCl3, δ, ppm]: 8.56 (m, 2H), 8.30 (m, 4H), 7.88-7.65 (m, 8H), 7.15 (m, 2H) 3.62 (m, 4H, 2CH2NO), 2.37 (m, 4H, 2CH2NH), 2.17 (m, 6H, 4CH2).
- Activation and coupling of 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline with N-(2-amino-ethyl)-(N,N′-dimethyl-N′-[2-(5-methyl-5H-indolo[3,2-b]quinolin-11-ylamino)-ethyl]-propane-1,3-diamine (prepared analogously to Example 15 from [2-[[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]carbamic acid tert-butyl ester and 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline gave the desired compound as a foam, (13 mg, 16%), 1H NMR [CDCl3 δ, ppm]: 8.58-8.40 (m, 4H), 8.01 (m, 2H), 7.84-7.64 (m, 4H), 7.63-7.55 (m, 2H), 7.42-7.27 (m, 4H), 4.61 (s, 6H, NCH3), 4.12 (m, 4H, 2CH2NH), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 6H, 4CH2), 2.15 (s, 6H, 2N(CH3)).
- Activation and coupling of 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline with N-(2-amino-ethyl)-(N,N′-dimethyl-N′-[2-(5-methyl-5H-indolo[3,2-b]quinolin-11-ylamino)-ethyl]-ethane-1,2-diamine (prepared analogously to Example 15 from [2-[[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]carbamic acid tert-butyl ester and 11-chloro-5-methyl-5H-indolo[3,2-b]quinoline gave the desired compound as a foam, (23 mg, 56%), 1H NMR [CDCl3 δ, ppm]: 8.66-8.21 (m, 4H), 8.01 (m, 2H), 7.84-7.64 (m, 4H), 7.63-7.55 (m, 2H), 7.42-7.27 (m, 4H), 4.91 (s, 6H, NCH3), 4.12 (m, 4H, 2CH2NH), 2.58 (m, 4H, 2CH2N(CH3)), 2.38 (m, 4H, 4CH2), 2.35 (s, 6H, 2N(CH3)).
- The in vitro cytotoxicity of the compounds of the present invention was evaluated by colorimetric assays with tetrazol salts (MTT) on Jurkat clon E6-1 and on GLC-4, human leukemia and carcinoma cell lines, respectively. This assay is based on the capacity of live cells to incorporate and reduce the MTT, with yellow colour in a red derivative. This reduction is done by the action of the mitochondrial enzyme succinate hydrogenase, only active in live cells. The intensity of observed colour is directly correlated with the quantity of live cells in the sample as it is described by Mosmann et al., J. Immunol. Methods 1983, vol. 65, p. 55. In all cases the concentrations used were up to 100 mikroM and times of incubation until 72 h. Table 1 shows the biological activity (IC50) of some compounds of formula (I)
-
TABLE 1 Biological activities. Compound (I) IC50 (μM) Jurkat clon E6-1 IC50 (μM) GLC-4 Ia 1.42 1.63 Ib 0.59 1.10 Ic 0.95 4.70 Id 3.37 3.57 Ie 5.13 2.88 If 7.16 3.64 Ip 0.26 0.67 Iu 18.7 15.70 Iv Not tested 16.73 Iw Not tested 1.08 Ix 1.21 19.57 Iy 7.94 19.08 Iz 5.02 11.53 Iac Not tested 5.88
Claims (22)
G1-L-G2 (I)
—(CH2)rNR′″(CH2)s—
—(CH2)rNR′″(CH2)sNR″″(CH2)t—
—(CH2)rNR′″(CH2)s—
—(CH2)rNR′″(CH2)sNR″″(CH2)t—
—(CH2)rNR′″(CH2)s—
—(CH2)rNR′″(CH2)sNR″″(CH2)t—
G1-L-G2 (I)
—(CH2)rNR′″(CH2)s—
—(CH2)rNR′″(CH2)sNR′″(CH2)t—
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/760,408 US20100331355A1 (en) | 2003-11-20 | 2010-04-14 | Substituted Quinolines for the Treatment of Cancer |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200302821 | 2003-11-20 | ||
ES200302821 | 2003-11-20 | ||
US10/580,140 US7728000B2 (en) | 2003-11-20 | 2004-11-18 | Substituted quinolines for the treatment of cancer |
PCT/EP2004/013106 WO2005054236A1 (en) | 2003-11-20 | 2004-11-18 | Substituted quinolines for the treatment of cancer |
US12/760,408 US20100331355A1 (en) | 2003-11-20 | 2010-04-14 | Substituted Quinolines for the Treatment of Cancer |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/013106 Continuation WO2005054236A1 (en) | 2003-11-20 | 2004-11-18 | Substituted quinolines for the treatment of cancer |
US11/580,140 Continuation US20070088412A1 (en) | 2005-10-13 | 2006-10-11 | System and device for heating or cooling shape memory surgical devices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100331355A1 true US20100331355A1 (en) | 2010-12-30 |
Family
ID=34639541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/580,140 Expired - Fee Related US7728000B2 (en) | 2003-11-20 | 2004-11-18 | Substituted quinolines for the treatment of cancer |
US12/760,408 Abandoned US20100331355A1 (en) | 2003-11-20 | 2010-04-14 | Substituted Quinolines for the Treatment of Cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/580,140 Expired - Fee Related US7728000B2 (en) | 2003-11-20 | 2004-11-18 | Substituted quinolines for the treatment of cancer |
Country Status (4)
Country | Link |
---|---|
US (2) | US7728000B2 (en) |
EP (1) | EP1687304A1 (en) |
JP (1) | JP2007511573A (en) |
WO (1) | WO2005054236A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101324781B1 (en) | 2011-04-29 | 2013-11-08 | (주)씨에스엘쏠라 | Noble photosensitizer for photovoltaic cell and photovoltaic cell prepared from the same |
US10008017B2 (en) | 2006-06-29 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Rendering tool information as graphic overlays on displayed images of tools |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005054236A1 (en) * | 2003-11-20 | 2005-06-16 | Crystax Pharmaceuticals S.L. | Substituted quinolines for the treatment of cancer |
ATE454149T1 (en) * | 2005-05-20 | 2010-01-15 | Crystax Pharmaceuticals S L | HALOGENATED QUINDOLINE DIMERS FOR THE TREATMENT OF CANCER |
EP2014698A1 (en) * | 2007-07-12 | 2009-01-14 | Crystax Pharmaceuticals S.L. | Polymers and their use as fluorescent labels |
JP6108696B2 (en) * | 2011-10-28 | 2017-04-05 | 国立大学法人 岡山大学 | Indolequinoline derivative, method for producing the derivative, and antimalarial agent and anticancer agent containing the derivative |
CN115160310B (en) * | 2022-05-10 | 2023-06-23 | 中国人民解放军北部战区总医院 | Alternanthene derivatives as CDK2/Topo I inhibitors, preparation method thereof and antitumor application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728000B2 (en) * | 2003-11-20 | 2010-06-01 | Crystax Pharmaceuticals | Substituted quinolines for the treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01228965A (en) * | 1988-03-10 | 1989-09-12 | Mect Corp | Condensed quinoline and condensed acridine, their production and anticancer agent containing said compounds |
JPH02256667A (en) * | 1988-12-27 | 1990-10-17 | Masatoshi Yamato | Condensed quinoline-based compound and production thereof |
US5362726A (en) * | 1993-02-12 | 1994-11-08 | Healthsearch, Inc. | Compound and method of treatment for falciparum malaria |
JPH10193807A (en) * | 1997-01-09 | 1998-07-28 | Konica Corp | Thermal transfer recording material and thermal transfer recording method |
WO1998045272A1 (en) * | 1997-04-07 | 1998-10-15 | Latrobe University | Topoisomerase inhibitors |
-
2004
- 2004-11-18 WO PCT/EP2004/013106 patent/WO2005054236A1/en not_active Application Discontinuation
- 2004-11-18 JP JP2006540327A patent/JP2007511573A/en active Pending
- 2004-11-18 EP EP04797988A patent/EP1687304A1/en not_active Withdrawn
- 2004-11-18 US US10/580,140 patent/US7728000B2/en not_active Expired - Fee Related
-
2010
- 2010-04-14 US US12/760,408 patent/US20100331355A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728000B2 (en) * | 2003-11-20 | 2010-06-01 | Crystax Pharmaceuticals | Substituted quinolines for the treatment of cancer |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10008017B2 (en) | 2006-06-29 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Rendering tool information as graphic overlays on displayed images of tools |
KR101324781B1 (en) | 2011-04-29 | 2013-11-08 | (주)씨에스엘쏠라 | Noble photosensitizer for photovoltaic cell and photovoltaic cell prepared from the same |
Also Published As
Publication number | Publication date |
---|---|
WO2005054236A1 (en) | 2005-06-16 |
JP2007511573A (en) | 2007-05-10 |
WO2005054236B1 (en) | 2005-08-18 |
US20070105784A1 (en) | 2007-05-10 |
US7728000B2 (en) | 2010-06-01 |
EP1687304A1 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100331355A1 (en) | Substituted Quinolines for the Treatment of Cancer | |
US7223833B1 (en) | Peptide nucleic acid conjugates | |
US8859490B2 (en) | Peptide nucleic acid monomers and oligomers | |
EP3152223B1 (en) | Mitomycin conjugate | |
EP0804456A1 (en) | Peptide nucleic acid conjugates | |
WO1996011205A9 (en) | Peptide nucleic acid conjugates | |
JP4805917B2 (en) | Camptothecin conjugated with a cyclic peptide at position 7 as a cell division inhibitor | |
Bailly et al. | Design, synthesis, DNA binding, and biological activity of a series of DNA minor‐groove‐binding intercalating drugs | |
US7049061B1 (en) | Stereochemical control of the DNA binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove | |
TW201004647A (en) | Novel dual targeting antitumoural conjugates | |
US11319341B2 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
US8008316B2 (en) | Azonafide derived tumor and cancer targeting compounds | |
US20120220537A1 (en) | 9-aminoacridine derivatives, their preparation and uses | |
WO2019047941A1 (en) | Amanitin antibody conjugate | |
EP0646596A1 (en) | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | |
US9056887B2 (en) | Minor groove binder phosphoramidites and methods of use | |
CA2172958A1 (en) | Anthracene derivatives for use as anticancer agent or dye | |
WO1997046551A1 (en) | Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors | |
RU2697519C1 (en) | Peptide agent comprising a psma-binding ligand based on a urea derivative, a method for production thereof and use thereof for preparing a conjugate with a drug and diagnostic agent | |
KR20080091103A (en) | Compound for the inhibition of apoptosis | |
Mehiri et al. | An efficient biodelivery system for antisense polyamide nucleic acid (PNA) | |
US7999101B2 (en) | Cationic lipids for the transfection of nucleic acids | |
Patino et al. | Modelling, synthesis and biological evaluation of an ethidium–arginine conjugate linked to a ribonuclease mimic directed against TAR RNA of HIV-1 | |
JP2007537243A (en) | 7-t-Butoxyiminomethylcamptothecin conjugated with an integrin antagonist at position 20 | |
Aymamí et al. | Substituted Quinolines for the Treatment of Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CRYSTAX PHARMACEUTICALS, S.L., SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AYMAMI BOFARULL, JUAN;COLL CAPELLA, MIQUEL;LLEBARIA SOLDEVILA, AMADEO;AND OTHERS;REEL/FRAME:026731/0556 Effective date: 20060425 Owner name: UNIVERSITAT POLITENCNICA DE CATALUNYA, SPAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AYMAMI BOFARULL, JUAN;COLL CAPELLA, MIQUEL;LLEBARIA SOLDEVILA, AMADEO;AND OTHERS;REEL/FRAME:026731/0556 Effective date: 20060425 Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AYMAMI BOFARULL, JUAN;COLL CAPELLA, MIQUEL;LLEBARIA SOLDEVILA, AMADEO;AND OTHERS;REEL/FRAME:026731/0556 Effective date: 20060425 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |